Table 1.
Baseline characteristics of the patients
| Variable | Non-Hodgkin Lymphoma Number, no. (%*) | Hodgkin Disease Number, no. (%*) |
|---|---|---|
| Number of patients: | 51 | 36 |
| Age in years (median, range) | 51 (34–64) | 31 (18–50) |
| Histology: | ||
| Classical Hodgkin | 36 (100) | |
| Indolent B-NHL | 13 (26) | |
| Follicular | 12 (24) | |
| Marginal zone | 1 (2) | |
| Aggressive B-NHL | 23 (45) | |
| Diffuse large B cell | 10 (20) | |
| Transformed follicular | 13 (25) | |
| Mantle cell | 15 (29) | |
| Disease status at transplantation: | ||
| CR | 14 (27) | 10 (28) |
| PR | 25 (49) | 18 (50) |
| SD | 6 (12) | 2 (6) |
| PD | 3 (6) | 6 (17) |
| Untreated | 3 (6) | 0 (0) |
| Marrow involvement at transplantation: | ||
| Yes | 7 (14) | 0 (0) |
| No | 27 (53) | 9 (25) |
| Unknown | 17 (33) | 27 (75) |
| Best response to chemotherapy: | ||
| CR | 39 (76) | 33 (92) |
| PR | 12 (24) | 3 (8) |
| Chemosensitivity at transplantation: | ||
| Yes | 42 (82) | 28 (78) |
| No | 5 (10) | 4 (11) |
| Untreated relapse | 4 (8) | 4 (11) |
| Number of prior therapies (median, range): | 4 (1–10) | 4 (2–8) |
| Prior autologous transplantation | ||
| Yes | 25 (49) | 34 (94) |
| No | 26 (51) | 2 (6) |
| Time from diagnosis to SCT, years (median, range): | 4 (0–16) | 3 (1–25) |
| LDH pre-transplantation: | ||
| Normal | 46 (90) | 32 (92) |
| Elevated | 5 (10) | 3 (8) |
| Graft source: | ||
| Peripheral blood | 50 (98) | 35 (97) |
| Bone marrow | 1 (2) | 1 (3) |
| CD34 dose (median, range)†: | 8.1 (2.4–23.3) | 7.2 (2.3–21.6) |
| Match: | ||
| MRD | 22 (43) | 11 (31) |
| MUD | 27 (53) | 22 (61) |
| Mismatched related | 1 (2) | 0 (0) |
| Mismatched unrelated | 1 (2) | 3 (8) |
| Gender match: | ||
| Female -> Male | 16 (31) | 6 (17) |
| GVHD prophylaxis: | ||
| CnI +/− steroids | 14 (27) | 3 (8) |
| CnI + Mtx | 5 (10) | 9 (25) |
| CnI + Siro +/− Mtx | 32 (63) | 24 (67) |
| Recipient CMV seropositive: | 17 (33) | 10 (28) |
| Donor CMV seropositive: | 17 (33) | 9 (25) |
CR indicates complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; SCT, allogeneic hematopoietic stem cell transplantation; MRD, matched related donor; MUD, matched unrelated donor; GVHD, graft-versus-host disease; CnI, calcineurin inhibitor (cyclosporine or tacrolimus); Mtx, methotrexate; Siro, sirolimus; and CMV, cytomegalovirus
*
Percentages may not add to 100 because of rounding
†
Cell dose unit is 106 per kilogram of recipient weight